XML 69 R38.htm IDEA: XBRL DOCUMENT v3.23.1
INCOME TAXES (Tables)
12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
SCHEDULE OF DOMESTIC AND FOREIGN COMPONENTS

The following table presents domestic and foreign components of consolidated loss before income taxes for the periods presented:

 

   December 31, 2022   December 31, 2021 
Domestic  $(15,954,750)  $(17,891,710)
Foreign   (5,344,967)    
Loss before provision for income taxes  $(21,299,717)  $(17,891,710)
SCHEDULE OF RECONCILIATIONS OF STATUTORY INCOME TAX RATE

A reconciliation of the statutory income tax rates and the Company’s effective tax rate is as follows:

 

   December 31, 2022   December 31, 2021 
Statutory federal income tax rate   21.00%   21.00%
State taxes, net of federal tax benefit   5.46%   6.63%
Non-deductible expenses   -1.36%   -1.19%
NOL expiration   -12.96%   -2.71%
Tax credit   2.42%   0.86%
Goodwill impairment   -4.50%   0.00%
Foreign rate differential   0.50%   0.00%
Change in FV of warrant liability   0.89%   5.54%
True-up   1.47%   -2.72%
Change in valuation allowance   -11.68%   -27.44%
Income taxes provision (benefit)   1.24%   -0.03%
SCHEDULE OF PROVISION FOR INCOME TAXES

Income tax expense for the year ended December 31, 2022 and 2021 consisted of the following:

 

   December 31, 2022   December 31, 2021 
   For the Years Ended 
   December 31, 2022   December 31, 2021 
Current        
US Federal  $   $ 
US State   7,000    5,000 
Foreign        
Total current provision   7,000    5,000 
Deferred          
US Federal   (236,000)   (1,268,000)
US State   (2,252,000)   (3,641,000)
Foreign   (272,000)    
Total deferred benefit   (2,760,000)   (4,909,000)
Change in valuation allowance   2,488,000    4,909,000 
Total provision (benefit) for income taxes  $(265,000)  $5,000 
SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES

The components of deferred tax assets and liabilities are as follows:

 

   December 31, 2022   December 31, 2021 
Deferred tax assets:          
Net operating loss  $33,540,000   $33,362,000 
Research and development credits   7,857,000    6,185,000 
Accrued expenses   1,020,000    757,000 
Patent       262,000 
Stock compensation   3,069,000    2,747,000 
Research and development expenses   1,196,000     
Fixed assets   280,000    282,000 
Total deferred income tax assets   46,962,000    43,595,000 
           
Deferred tax liabilities:          
Intangible assets   (1,324,000)   (34,000)
Right-of-use asset   (382,000)   (436,000)
Total deferred income tax liabilities   (1,706,000)   (470,000)
           
Net deferred income tax assets   45,256,000    43,125,000 
Valuation allowance   (45,614,000)   (43,125,000)
Deferred tax asset, net of allowance  $(358,000)  $